Trial Profile
Effect of Cabergoline on Subendometrial Vasculaity During ICSI Cycles and Pregnancy Outcome
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabergoline (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Pharmacodynamics
- 03 Dec 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.
- 03 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2017.
- 22 Jun 2015 Planned End Date changed from 1 Nov 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.